Table 3 Freezing associated factors
From: Profile of idiopathic parkinson’s disease in Moroccan patients
Independant variables | n (%) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
OR | CI 95% | p | OR | CI 95% | p | ||
Age of onset | |||||||
> 65 years | 4 (14,3) | 1 | |||||
< 45 years | 5 (33,3) | 3 | 0,66- 13,5 | 0,15 | |||
45-54 years | 5 (17,9) | 1,3 | 0,31- 5,4 | 0,71 | |||
55- 65 years | 6 (14,3) | 1 | 0,25- 3,9 | 1,00 | |||
Gender | - | 0,35 | 0,10- 1,10 | 0,078 | |||
Disease duration* | 5 [3;9] | 1,1 | 1,03- 1,26 | 0,009 | 1 | 0,99-1,01 | 0,07 |
Dysautonomic troubles | 13 (26,0) | 1,5 | 0,78- 2,90 | 0,22 | |||
Cognitive troubles | 4 (30,8) | 2,3 | 0,65- 8,70 | 0,18 | |||
L-dopa treatment duration* | 5 [3;9] | 1,01 | 1,003- 1,02 | 0,008 | 1 | 1,1-11,8 | 0,06 |
LED (mg) ** | 667 ± 446 | 1,001 | 1,000- 1,002 | 0,02 | |||
≤ 600 mg | 5 (7,8) | 1 | |||||
> 600 mg | 15(32,6) | 0,17 | 0,05- 0,50 | 0,002 | 4.8 | 1,56-14,9 | 0,006 |
Treatment | |||||||
Dopaminergic agonists | 0 | 1 | |||||
Levodopa | 9 (22,0) | 0,92 | 0,33- 2,50 | 0,87 | |||
DA + levodopa | 11 (23,4) | 0 | 0,71 | ||||